Cargando…

EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe

For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. EORTC‐SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular...

Descripción completa

Detalles Bibliográficos
Autores principales: de Rojas, Teresa, Kasper, Bernd, Van der Graaf, Winette, Pfister, Stefan M., Bielle, Franck, Ribalta, Teresa, Shenjere, Patrick, Preusser, Matthias, Fröhling, Stefan, Golfinopoulos, Vassilis, Morfouace, Marie, McCabe, Martin G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383917/
https://www.ncbi.nlm.nih.gov/pubmed/31465545
http://dx.doi.org/10.1002/ijc.32651
_version_ 1783563518954438656
author de Rojas, Teresa
Kasper, Bernd
Van der Graaf, Winette
Pfister, Stefan M.
Bielle, Franck
Ribalta, Teresa
Shenjere, Patrick
Preusser, Matthias
Fröhling, Stefan
Golfinopoulos, Vassilis
Morfouace, Marie
McCabe, Martin G.
author_facet de Rojas, Teresa
Kasper, Bernd
Van der Graaf, Winette
Pfister, Stefan M.
Bielle, Franck
Ribalta, Teresa
Shenjere, Patrick
Preusser, Matthias
Fröhling, Stefan
Golfinopoulos, Vassilis
Morfouace, Marie
McCabe, Martin G.
author_sort de Rojas, Teresa
collection PubMed
description For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. EORTC‐SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in February 2019 across Europe, will recruit 100 AYA patients (aged 12–29 years) with newly diagnosed or relapsed high‐grade gliomas and high‐grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Formalin‐fixed tumor tissue and whole blood from study participants will be prospectively collected with clinical data and stored centrally at the Integrated BioBank of Luxembourg. Whole exome sequencing of matched tumor and blood, and tumor RNA sequencing and DNA methylation profiling will be performed at the German Cancer Research Center, Heidelberg, Germany. Virtual central pathology review of scanned diagnostic slides will be undertaken by an international expert panel, and diagnostic material returned to the participating centers. A multidisciplinary molecular tumor board will release a clinically validated report to referring clinicians within 4–6 weeks after biopsy. SPECTA‐AYA constitutes a major opportunity to gain knowledge about the tumor biology of this unique age group. It incorporates notable innovative aspects: AYA specificity, pan‐European academic collaboration, centralized biobanking, comprehensive molecular profiling and virtual central pathology review, among others. SPECTA‐AYA will help untangle the tumor particularities of AYAs with cancer and aims to improve their access to novel drugs and personalized medicine.
format Online
Article
Text
id pubmed-7383917
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-73839172020-07-27 EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe de Rojas, Teresa Kasper, Bernd Van der Graaf, Winette Pfister, Stefan M. Bielle, Franck Ribalta, Teresa Shenjere, Patrick Preusser, Matthias Fröhling, Stefan Golfinopoulos, Vassilis Morfouace, Marie McCabe, Martin G. Int J Cancer Molecular Cancer Biology For most adolescent and young adult (AYA) cancers, age‐specific molecular features are poorly understood. EORTC‐SPECTA, an academic translational research infrastructure for biomaterial collection, will explicitly recruit AYA patients and will therefore collect empirical data to bridge the molecular gap between pediatric and adult oncology. The initial pilot study, activated in February 2019 across Europe, will recruit 100 AYA patients (aged 12–29 years) with newly diagnosed or relapsed high‐grade gliomas and high‐grade bone and soft tissue sarcomas. The primary objective of the pilot is to determine feasibility and recruitment rates. Formalin‐fixed tumor tissue and whole blood from study participants will be prospectively collected with clinical data and stored centrally at the Integrated BioBank of Luxembourg. Whole exome sequencing of matched tumor and blood, and tumor RNA sequencing and DNA methylation profiling will be performed at the German Cancer Research Center, Heidelberg, Germany. Virtual central pathology review of scanned diagnostic slides will be undertaken by an international expert panel, and diagnostic material returned to the participating centers. A multidisciplinary molecular tumor board will release a clinically validated report to referring clinicians within 4–6 weeks after biopsy. SPECTA‐AYA constitutes a major opportunity to gain knowledge about the tumor biology of this unique age group. It incorporates notable innovative aspects: AYA specificity, pan‐European academic collaboration, centralized biobanking, comprehensive molecular profiling and virtual central pathology review, among others. SPECTA‐AYA will help untangle the tumor particularities of AYAs with cancer and aims to improve their access to novel drugs and personalized medicine. John Wiley & Sons, Inc. 2019-09-14 2020-08-15 /pmc/articles/PMC7383917/ /pubmed/31465545 http://dx.doi.org/10.1002/ijc.32651 Text en © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Molecular Cancer Biology
de Rojas, Teresa
Kasper, Bernd
Van der Graaf, Winette
Pfister, Stefan M.
Bielle, Franck
Ribalta, Teresa
Shenjere, Patrick
Preusser, Matthias
Fröhling, Stefan
Golfinopoulos, Vassilis
Morfouace, Marie
McCabe, Martin G.
EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
title EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
title_full EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
title_fullStr EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
title_full_unstemmed EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
title_short EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
title_sort eortc specta‐aya: a unique molecular profiling platform for adolescents and young adults with cancer in europe
topic Molecular Cancer Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7383917/
https://www.ncbi.nlm.nih.gov/pubmed/31465545
http://dx.doi.org/10.1002/ijc.32651
work_keys_str_mv AT derojasteresa eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT kasperbernd eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT vandergraafwinette eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT pfisterstefanm eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT biellefranck eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT ribaltateresa eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT shenjerepatrick eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT preussermatthias eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT frohlingstefan eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT golfinopoulosvassilis eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT morfouacemarie eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope
AT mccabemarting eortcspectaayaauniquemolecularprofilingplatformforadolescentsandyoungadultswithcancerineurope